The India-based formulations contract manufacturer, Kemwell Biopharma Pvt. Ltd., has expanded its state-of-the-art pharmaceutical development labs in Bangalore, including a 7,500 sq ft cGMP pilot facility to support pharmaceutical projects from pre-formulation to finished products.
"We are seeing an increasing demand for contract development services in the global market. Kemwell has invested in a world-class facility with experienced scientists to meet the growing needs of its customers. With the new labs, Kemwell continues to build upon its ongoing commitment to be a high-quality one-stop shop service provider for its customers," said Anurag Bagaria, managing director.
The 15,000 sq ft facility has capabilities to handle solids, injectables (large and small molecules), liquids and semi-solids dosage forms. Currently, the labs have 80 scientists with the ability to scale up to 150 scientists. Our scientists have extensive expertise in developing formulations for conventional and specialized dosage forms, including sustained release (SR) and modified release (MR) solids, liquids, and injectables.
Kemwell has the capability to offer customers pharmaceutical services that include pre-formulation, formulation development, analytical method development and validation, process optimization and scale-up, packaging development, pivotal batch manufacturing, stability batch manufacturing, stability studies, clinical batch manufacturing, labelling for blinded studies, preparation of placebo batches, tech transfer as well as commercial manufacturing. This enhanced facility coupled with our commercial manufacturing network on the same site, enables Kemwell to offer a wider scale of services for the development, testing and commercialization of large and small molecules. In Sweden, Kemwell also provides services for QP release. Says Anurag Bagaria: "Kemwell's sites in India and Sweden can work in harmony to provide the customer with the best solution from both worlds".